Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2003
12/04/2003WO2003063846A3 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
12/04/2003WO2003062200A3 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
12/04/2003WO2003061593A3 Novel targeted compositions for diagnostic and therapeutic use
12/04/2003WO2003061579A3 Phthalocyanine and porphyrazine pharmaceutical compositions
12/04/2003WO2003060468A3 Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease
12/04/2003WO2003060096A3 Assay for the detection of factors that modulate the expression of ingap
12/04/2003WO2003057168A3 Cancer-associated epitope
12/04/2003WO2003050122A3 Mitotic kinesin inhibitors
12/04/2003WO2003046552A3 Screening method for compounds that modulate neuronal activity
12/04/2003WO2003045910A3 Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
12/04/2003WO2003040725A3 Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen
12/04/2003WO2003031462A3 Nogo receptor-mediated blockade of axonal growth
12/04/2003WO2003029417A3 Nutrient medium for maintaining neural cells in injured nervous system
12/04/2003WO2003028537A3 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
12/04/2003WO2003024405A3 Methods and compositions for inhibiting the proliferation of prostate cancer cells
12/04/2003WO2003022217A3 Treatment of excessive radiation (e.g. sunburn) exposure
12/04/2003WO2003020280A3 Compositions and use thereof in the treatment of cancer
12/04/2003WO2003017991A3 Injection solution containing a dihydropyridin derivative
12/04/2003WO2003015748A3 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
12/04/2003WO2003014145A3 Peptides that bind to atherosclerotic lesions
12/04/2003WO2003011264A3 Betacarboline derivatives as gaba a-receptor-modulators having nmda-antagonistic activity for treating diseases of the central nervous system
12/04/2003WO2003008579A3 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
12/04/2003WO2003006996A3 Natural ligand of gpcr chemr23 and uses thereof
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002099068A3 LCES AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/04/2003WO2002098515A3 Topical treatments using alkanolamines
12/04/2003WO2002094186A3 Urazole compounds useful as anti-inflammatory agents
12/04/2003WO2002086090A3 Identification of essential genes of aspegillus fumigatus and methods of use
12/04/2003WO2002074314A9 Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
12/04/2003WO2002074193A3 METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
12/04/2003WO2002073208A3 Anti-epileptogenic agents
12/04/2003WO2002070708A3 Glutamate receptor modulatory proteins and nucleic acids encoding them
12/04/2003WO2002070555A3 Method of modulating the proliferation of medullary thyroid carcinoma cells
12/04/2003WO2002069985A8 Immune response potentiation
12/04/2003WO2002064742A3 Compounds effecting neuron remodeling and assays for same
12/04/2003WO2002058694A3 Method of treating hematologic tumors and cancers using beta lapachone
12/04/2003WO2002057427A3 Mammalian tumor susceptibility gene products and their uses
12/04/2003WO2002030462A3 Hedgehog antagonists, methods and uses related thereto
12/04/2003US20030225309 Radioactive compositions and methods of use thereof
12/04/2003US20030225155 Treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, heavy metal poisoning and immunogical diseases with thiophene-2-carboxylic acid, 2-furoic acid or derivatives
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225150 Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
12/04/2003US20030225141 Thiazole derivatives
12/04/2003US20030225132 Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders
12/04/2003US20030225123 Antihypertensive agents and use
12/04/2003US20030225118 Tamsulosin, or an acid addition salt thereof with a 5 alpha-reductase inhibitor.
12/04/2003US20030225117 Use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes
12/04/2003US20030225114 Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4- oxopyrimidines
12/04/2003US20030225096 Administering a growth hormone secretagogue.
12/04/2003US20030225095 Method of affecting sleep and sleep-related behaviors
12/04/2003US20030225091 Aryl carboxylic acids and tetrazoles for treating diabetes, especially type II diabetes
12/04/2003US20030225089 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
12/04/2003US20030225071 N-heterocyclic amides and carbamates
12/04/2003US20030225067 Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
12/04/2003US20030225060 Acylated piperidine derivatives as melanocortin-4 receptor agonists
12/04/2003US20030225054 Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030225046 Through modulation of the interaction of such hormone receptors with phosphatidylinositol-3 kinase
12/04/2003US20030225041 Topical application to the eye of an acetylcholinesterase inhibitor such as echothiophate iodide to treat color blindness, ocular hypertension and glaucoma, and progression of myopia Strabismus Stargardts or pupil dilation.
12/04/2003US20030225037 Method for the treatment or prevention of Flaviviridea viral infection using nucleoside analogues
12/04/2003US20030225031 Liquid or gel solution for nasal administration also containing a permeation-enhancement agent for transmucosal drug uptake.
12/04/2003US20030225029 Dosing regimen for gemcitabine HCV therapy
12/04/2003US20030225020 Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
12/04/2003US20030225002 Aminosulfonyloxymethyl-substituted pyrans or cyclohexanes (e.g., topiramate) for relieving migraines and associated symptoms (nausea, vomiting, photophobia, phonophobia, etc.) administered with an antimigraine agent
12/04/2003US20030224983 Stimulation of beta cell proliferation
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224466 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore
12/04/2003US20030224414 Comprises nucleotide sequences coding enzymatic polypeptide for diagnosis, prognosis and treatment of cell proliferative disorders
12/04/2003US20030224362 Diagnosing alcoholism using presence of mutation in neuropeptide y gene; drug abuse; restriction fragment length polymorphisms; immunoassay
12/04/2003US20030224360 Interventions to mimic the effects of calorie restriction
12/04/2003US20030224348 Methods of screening for SCAP antagonists
12/04/2003US20030224347 Pharmaceutical compositions
12/04/2003US20030224343 Kappa-PVIIA-related conotoxins as organ protectants
12/04/2003US20030224070 Fertility kit
12/04/2003US20030224064 Anti-acne compositions and methods of use
12/04/2003US20030224058 Nanoparticulate fibrate formulations
12/04/2003US20030224057 Continuous method for preparing pharmaceutical granules
12/04/2003US20030224046 Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
12/04/2003US20030224040 Genomic screen for epigenetically silenced genes associated with cancer
12/04/2003US20030224039 Infusing at a low temperature below the phase transition of lipid; use for intravenous administration, inhalation administration; no toxic solvents, simple process; bactericides
12/04/2003US20030224008 Novel uses for anti-malarial therapeutic agents
12/04/2003US20030223990 A novel gene (designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers. 193P1E1 provides
12/04/2003US20030223959 Diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological
12/04/2003US20030223958 Use of interleukin-19 to treat ovarian cancer
12/04/2003US20030223956 Macromers having a backbone comprising a polymeric backbone comprising units with a 1,2- diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and other modifiers. When crosslinked, the macromers
12/04/2003US20030223941 Methods for modulating phototoxicity
12/04/2003CA2771788A1 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
12/04/2003CA2490541A1 Copper lowering treatment of inflammatory and fibrotic diseases
12/04/2003CA2490062A1 Methods of treating bacterial infections and diseases associated therewith
12/04/2003CA2487655A1 Methods and compositions for inhibiting hiv replication
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487303A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003CA2487273A1 Agents and methods for the treatment of disorders associated with oxidative stress
12/04/2003CA2487268A1 Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
12/04/2003CA2487167A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003CA2487143A1 Regulation of novel human asparagine-hydroxylases
12/04/2003CA2487117A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection
12/04/2003CA2487112A1 Neuregulin based methods and compositions for treating cardiovascular diseases
12/04/2003CA2487073A1 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003CA2486909A1 Compositions and method for transmucosal drug delivery and cryoprotection
1 ... 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 ... 1151